Saturday 17 October 2026
Export SANA’s income statement to Excel — free account
Sana Biotechnology, Inc.
SANA Healthcare Biotechnology
In the quarter to June 2026, EPS grew 43.6% and free cash flow fell 5.46%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
2.27
0.21
−8.47%
Follow SANA
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
— | 16.50 | 7.47 | 12.22 | 5.62 | 3.99 | 3.31 | 3.54 | 1.89 |
Net Debt/EBITDA |
— | 3.77 | 1.00 | 1.35 | 1.59 | 1.67 | 0.76 | 0.61 | 0.60 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | 1.02 | 0.65 | 0.48 | 0.71 | 1.08 | 0.90 | 0.84 | 0.59 |
Capex/Depreciation |
— | 0.00 | (14.31) | (4.03) | (2.70) | (1.34) | (1.14) | (2.16) | 0.04 |
| — | 16.98% | 168.16% | 101.22% | (231.64%) | (43.90%) | (72.00%) | (99.17%) | (118.70%) | |
| — | (77.92%) | (58.23%) | (49.81%) | (38.28%) | (27.61%) | (40.81%) | (50.03%) | (53.20%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | (125.67%) | (245.99%) | (233.45%) | (180.99%) | (854.59%) |
Return on Tangible Assets |
— | (41.40%) | (85.56%) | (71.36%) | (67.88%) | (67.39%) | (128.92%) | (138.44%) | (252.09%) |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.48 | 0.27 | 0.18 | 0.24 | 0.35 | 0.40 | 0.48 |
Share Based Compensation of Revenue |
— | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
— | (0.07) | (22.77) | (12.44) | (1.69) | (1.65) | (1.41) | (1.11) | (0.57) |
Cash per Share |
— | 0.17 | 28.35 | 29.07 | 3.31 | 2.28 | 1.07 | 0.68 | 0.56 |
Shareholders Equity per Share |
— | 0.18 | (29.07) | (32.36) | 4.38 | 2.65 | 1.48 | 1.08 | 0.64 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 0.18 | (29.07) | (32.36) | 4.38 | 2.65 | 1.48 | 1.08 | 0.64 |
Free Cash Flow |
— | (13.49) | (111.64) | (161.85) | (280.92) | (310.93) | (273.61) | (256.58) | (143.33) |
Working Capital |
— | 31.00 | 124.94 | 353.02 | 458.87 | 332.93 | 149.03 | 115.38 | 69.95 |
Capital Expenditures |
— | (0.46) | (26.12) | (23.87) | (29.86) | (20.88) | (20.03) | (33.43) | 0.49 |
Net Current Asset Value |
— | 31.00 | (413.47) | (767.01) | 157.20 | 121.03 | (64.28) | (89.71) | (107.33) |
| Other line items | |||||||||
Quick Ratio |
— | 15.50 | 7.19 | 12.03 | 5.55 | 3.86 | 3.24 | 3.44 | 1.81 |
Depreciation/Fixed assets |
— | 0.00 | 0.07 | 0.13 | 0.17 | 0.23 | 0.25 | 0.20 | 0.47 |
Cash ROIC |
— | (21.09%) | 3,136.01% | 377.11% | (21.96%) | (33.46%) | (55.10%) | (63.07%) | (47.23%) |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | (0.07) | (17.44) | (10.60) | (1.51) | (1.54) | (1.30) | (0.97) | (0.57) |
Capex per Share |
— | 0.00 | (5.33) | (1.83) | (0.18) | (0.11) | (0.10) | (0.14) | 0.00 |
Average Payables |
— | (0.21) | (0.21) | 0.92 | 2.24 | 2.54 | 3.48 | 4.66 | 3.44 |
Average Assets |
— | 17.00 | 224.60 | 572.74 | 929.85 | 976.06 | 694.01 | 533.16 | 458.96 |
Average Common Equity |
— | (78.00) | (77.77) | (281.86) | 153.66 | 613.91 | 393.41 | 269.01 | 205.69 |
Capex to Sales |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates